Relief Therapeutics
Relief Therapeutics was a Swiss clinical-stage biopharmaceutical company. Following its December 2025 merger with NeuroX Group, the combined entity operates as MindMaze Therapeutics, integrating digital neurotherapeutics platforms with pharmaceutical pipelines for stroke, Parkinson's, PKU, and rare lung diseases.
- Company typePublic
- Founded2013
- HeadquartersLausanne, Switzerland
- Headcount51–100
- GTM typeB2B
- OfferingSoftware
Relief Therapeutics firmographics
Firmographics- Name
- Relief Therapeutics
- Legal name
- Relief Therapeutics Holding SA
- Website
- https://relieftherapeutics.com
- Company type
- Public
- Founded year
- 2013
- Operating status
- Acquired
- Headcount range
- 51–100 employees
- Short description
- Relief Therapeutics was a Swiss clinical-stage biopharmaceutical company. Following its December 2025 merger with NeuroX Group, the combined entity operates as MindMaze Therapeutics, integrating digital neurotherapeutics platforms with pharmaceutical pipelines for stroke, Parkinson's, PKU, and rare lung diseases.
- Ownership category
- akta.pro rank
Relief Therapeutics industry classification
Industry- Product category
- Digital Neurotherapeutics
- NAICS
- Offices of Physical, Occupational and Speech Therapists, and Audiologists (621340), Home Health Care Services (62161), Other Computer Related Services (541519), Offices of Physical, Occupational and Speech Therapists, and Audiologists (62134)
- SIC
- Services-Misc Health & Allied Services, Nec (8090), Services-Health Services (8000), Services-Home Health Care Services (8082), Services-Prepackaged Software (7372)
- akta.pro primary industry
- Digital Rehabilitation & Physical Therapy Therapeutics (HLACANAJ)
- akta.pro secondary industries
- Behavioral Health & Neurocognitive Therapeutics (Digital) (HLACANAI), Neurology & CNS Specialty Pharmaceuticals (HLAIACAC), Medication Adherence, Digital Therapeutics & Remote Coaching (condition-specific programs) (HLALAFAF), Chronic Disease Management Pathways (e.g., diabetes, CHF, COPD) (HLACAGAG)
Keywords
Where Relief Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Lausanne
- HQ country
- Switzerland
- HQ region
- Europe
Offices1 record
Markets served
Relief Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Operations, Personnel, Marketing or Sales
Revenue model
- Digital Neurotherapeutics: Revenue generated from commercially available precision neurotherapeutic solutions deployed in clinical settings, including MindMotion GO, MindPod, and other digital therapy products. The company generates revenue from therapy delivery and related services.
- Pharmaceutical Products: Revenue from pharmaceutical pipeline including RLF-OD032 (sapropterin dihydrochloride for phenylketonuria) and aviptadil for rare lung diseases. Products were in various stages from development to commercial.
- Home-Based Therapy: Revenue from CMS Category III reimbursed home-based AI-driven neurorehabilitation services, representing a reimbursable clinical service pathway.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Enterprise/Hospital contracts |
| Subscription | Pay-as-you-go | Home-based therapy reimbursement |
Go-to-market motion1 record
Distribution channels4 records
Marketing channels3 records
Relief Therapeutics product offering
Product offeringCore offering
Relief Therapeutics develops and commercializes precision neurotherapeutic solutions combining behavioral therapy, proprietary software, smart peripheral devices, and AI-driven data analytics for patients with neurological conditions including stroke, Parkinson's disease, Alzheimer's, and traumatic brain injury. The product portfolio spans the MindMaze Platform ecosystem (MindPod, MindMotion GO, Izar, Physilog, ToapRun, Companion) deployed in hospitals and home settings, complemented by a pharmaceutical pipeline addressing rare diseases such as RLF-OD032 for phenylketonuria and aviptadil for rare lung diseases.
Product overview
Relief Therapeutics, now operating as MindMaze Therapeutics following its December 2025 merger with NeuroX Group, offers a platform-plus-modules architecture combining precision digital neurotherapeutics with pharmacological treatments. The MindMaze Platform serves as the core ecosystem integrating behavioral neurotherapeutics, software, devices, and data. The therapy and monitoring portfolio includes MindPod (immersive gaming-based motor and cognitive recovery), MindMotion GO (neurorehabilitation system for clinical and home settings), Izar (smart hand training peripheral), Physilog (3D motion analytics for digital biomarkers), ToapRun, and Companion. The drug development pipeline encompasses treatments for rare diseases including RLF-OD032 (phenylketonuria) and aviptadil (inhaled formulation for rare lung diseases). The combined entity holds 27+ completed clinical studies, 11 regulatory clearances, and processes over 1.2 billion data points per month.
Differentiator
Problem solved
Functional benefit
Brands
- MindPod: The immersive experience platform for brain recovery and learning with animated gaming environment designed to promote recovery of motor skill and cognitive function
- MindMotion GO
- Izar
- Physilog
- ToapRun
- Companion
- RLF-OD032
Products and services
- MindMaze Platform A treatment ecosystem redefining brain health and recovery that integrates behavioral neurotherapeutics, software, devices, and data into a unified precision neurotherapeutic platform; deployed at leading clinical centers worldwide for hospitals and neurorehabilitation facilities.
- MindPod Immersive experience platform featuring an animated gaming environment designed to promote recovery of motor skill and cognitive function with emotionally-engaging experiences; for patients with neurological conditions in clinical neurorehabilitation settings.
- MindMotion GO First-of-its-kind neurorehabilitation system providing effective behavioral neurotherapeutics in both clinical and home settings, designed to keep patients training for longer across the continuum-of-care; for hospitals, neurorehabilitation facilities, and home-based therapy.
- Izar Proprietary smart peripheral designed to improve hand motor function in patients with neurological conditions including stroke, Parkinson's, Alzheimer's, and traumatic brain injury; deployed in neurorehabilitation settings.
- Physilog Solution delivering powerful 3D motion analytics to capture, measure, and analyze a new generation of digital biomarkers for patient-centric digital motion assessments; used by clinical and research customers.
- ToapRun Therapy and monitoring device listed as part of the proprietary portfolio of solutions for precision neurotherapeutics; deployed alongside the MindMaze therapy and monitoring portfolio.
- Companion Therapy and monitoring solution included in the MindMaze portfolio of precision neurotherapeutic solutions; supports patient recovery and monitoring.
- RLF-OD032 Liquid formulation of sapropterin dihydrochloride for treating phenylketonuria (PKU), shown bioequivalent to KUVAN Powder in pivotal study with plans for new drug application submission in early 2026; U.S. and Canadian rights sold to MindMaze Therapeutics for $3 million upfront plus royalties.
Quantifiable outcome
- 60% increase in delivered therapy per day
- +2 more outcomes
Companies that use Relief Therapeutics
Customer profileNamed customers1 record
Segments4 records
Ideal customer profiles2 records
Relief Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability4 records
Feature6 records
Relief Therapeutics partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered minor, key and supporting.
- MindMaze Therapeutics (RLF-OD032 buyer)minorMindMaze Therapeutics is purchasing U.S. and Canadian rights to RLF-OD032 program for $3 million upfront plus royalties. The program was a legacy asset from Relief Therapeutics.
- Vibra HealthcarekeyMulti-site real-world evidence program conducted with Vibra Healthcare demonstrating statistically significant improvements in mobility and self-care outcomes, including a 60% increase in delivered therapy per day and 77% of patients reporting improved recovery.
- SwissNeuroRehab ConsortiumkeyCHF 11.2 million Innosuisse-backed national consortium involving Swiss university hospitals for national evidence generation program in digital neurorehabilitation.
- NICE (National Institute for Health and Care Excellence)supportingAligning with NICE evaluation frameworks in the United Kingdom to support future reimbursement and adoption of neurotherapeutics.
Scale indicators15 records
Recent moves8 records
Expansion highlights6 records
Relief Therapeutics competitors and assessment
Company assessmentDirect peers
- Neofect: Neofect delivers smart rehabilitation solutions including the Rapael Smart Glove and home-based therapy apps for stroke recovery. Directly comparable to Izar and MindMotion GO on home-based, gamified neurorehabilitation.
- Penumbra (REAL Immersive System): Penumbra offers the REAL Immersive System, a VR-based neurorehabilitation platform for stroke and neurological recovery. Directly comparable to MindMotion GO and MindPod as a digital neurotherapeutic for clinical and home settings.
- Bionik Laboratories: Bionik Laboratories offers robotic rehabilitation technologies for upper limb recovery following stroke and neurological injury. Directly comparable to MindMotion GO and Izar for motor skill recovery in clinical settings.
- Saebo: Saebo provides functional orthotics and rehabilitation products for stroke and neurological patients, including hand/grip devices and therapy software. Directly comparable to Izar and Companion as therapy and monitoring solutions for neurological recovery.
- Hocoma / DIH Medical: Hocoma, now part of DIH, develops robotic and sensor-based neurorehabilitation devices (Lokomat, Armeo). Directly comparable as a clinical neurorehabilitation device vendor serving hospitals and rehab centers worldwide.
Broad incumbents
- Medtronic (Neuromodulation): Medtronic operates a major neuromodulation business (deep brain stimulation for Parkinson's, spinal cord stimulation) adjacent to MindMaze's neurological disease focus. Comparable as a broad incumbent in neurology devices with overlapping therapy delivery mechanisms.
- BioMarin Pharmaceutical: BioMarin markets KUVAN (sapropterin) for phenylketonuria, the reference listed drug for Relief's RLF-OD032. Comparable as a CNS/specialty pharmaceutical incumbent in the PKU space and broader rare disease neurology.
Emerging players
- Flint Rehab: Flint Rehab develops low-cost, clinically validated neurorehabilitation devices (MusicGlove, FitMi) used in clinic and home. Comparable to MindPod and MindMotion GO as digital neurotherapeutic solutions for stroke and motor recovery.
- Constant Therapy (Linus Health): Constant Therapy, part of Linus Health, provides digital cognitive, speech, and language therapy across clinical and home settings. Comparable as a software-driven neurorehabilitation platform targeting cognitive recovery alongside motor function.
Regional players
- Elekta (Elekta ONE / Kaiku): Elekta, via its Kaiku Health subsidiary, delivers digital patient monitoring and symptom tracking for chronic conditions including oncology; comparable platform architecture for digital neuro-monitoring and patient-reported outcomes. Primary footprint is European/oncology rather than competing directly in US neurorehab.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
Relief Therapeutics social profiles
Digital presenceRelief Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Relief Therapeutics leadership team
Management profileNumber of profiles
Profiles10 records
Relief Therapeutics subsidiaries and ownership
Company hierarchySubsidiaries2 records
Relief Therapeutics funding detail
Funding detailFunding overview
Funding rounds13 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Relief Therapeutics M&A and investment
M&A and investmentM&A4 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Relief Therapeutics
What does Relief Therapeutics do?
Relief Therapeutics develops and commercializes precision neurotherapeutic solutions combining behavioral therapy, proprietary software, smart peripheral devices, and AI-driven data analytics for patients with neurological conditions including stroke, Parkinson's disease, Alzheimer's, and traumatic brain injury. The product portfolio spans the MindMaze Platform ecosystem (MindPod, MindMotion GO, Izar, Physilog, ToapRun, Companion) deployed in hospitals and home settings, complemented by a pharmaceutical pipeline addressing rare diseases such as RLF-OD032 for phenylketonuria and aviptadil for rare lung diseases.
Is Relief Therapeutics a public or private company?
Relief Therapeutics is a public company. It is classified as public and is currently acquired.
When was Relief Therapeutics founded?
Relief Therapeutics was founded in 2013. It employs 51 to 100 people.
Where is Relief Therapeutics based?
Relief Therapeutics is headquartered in Lausanne, Switzerland, in the Europe region.
How does Relief Therapeutics make money?
Three revenue lines are on record. Digital Neurotherapeutics are the primary driver. The others are pharmaceutical Products and home-Based Therapy.
Who are Relief Therapeutics's main competitors?
Direct peers on record are Neofect, Penumbra (REAL Immersive System), Bionik Laboratories, Saebo and Hocoma / DIH Medical. Broad incumbents are Medtronic (Neuromodulation) and BioMarin Pharmaceutical. Emerging players are Flint Rehab and Constant Therapy (Linus Health). Elekta (Elekta ONE / Kaiku) is listed as a regional player.
Does Relief Therapeutics have an API?
No public API is recorded for Relief Therapeutics.
What industry is Relief Therapeutics in?
Relief Therapeutics's product category is Digital Neurotherapeutics. Its primary akta.pro industry code is HLACANAJ, Digital Rehabilitation & Physical Therapy Therapeutics, with a secondary code of HLACANAI, Behavioral Health & Neurocognitive Therapeutics (Digital). Its NAICS code is 621340 and its SIC code is 8090.